MDACC Study No:2010-0438 ( NCT No: NCT01340976)
Title:A Phase 1 Safety Study of LY2787106 in Patients with Cancer and Anemia
Principal Investigator:Saroj Vadhan-Raj
Treatment Agent:LY2787106
Study Status:Closed
Study Description:The goal of this clinical research study is to find out if LY2787106 along or
combined with oral iron supplement can be safely given to patients with cancer
and anemia. Researchers want to learn more about how much study drug is and
will effect different areas of the body at different time points.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma; Myeloma; Sarcoma; Solid Tumors
Phase of Study:Phase I
Treatment Agents:LY2787106
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Eli Lilly and Company
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Saroj Vadhan-Raj
Dept:Cytokines and Supportive Care
For Clinical Trial Enrollment:713-792-7966
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults